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Introduction
The regulation of cell proliferation and cell survival in
breast cancer is a complex interplay between steroid hor-
mones, growth factors and their receptors. The under-
standing of the signalling pathways involved in these
processes may help us find predictive factors for tumour
aggressiveness and therapy resistance. Already recog-
nised is the importance of the oestrogen receptor (ER)
status of the tumour for predicting the benefit from
endocrine treatment [1].
Although it has not yet been fully established from clinical
materials, experimental studies suggest that overexpres-
sion of different growth factor receptors in breast cancer
makes cells less sensitive to tamoxifen and other cytotoxic
drugs. These receptors include insulin-like growth factor
CI = confidence interval; CMF = cyclophosphamide–methotrexate–5-fluorouracil; ER = oestrogen receptor; FITC = fluorescein isothiocyanate;
pAkt = phosphorylated Akt; PI3-K = phosphatidylinositol 3-kinase; RR = rate ratio.
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Abstract
Background: The serine/threonine kinase Akt, or protein
kinase B, has recently been a focus of interest because of its
activity to inhibit apoptosis. It mediates cell survival by acting as
a transducer of signals from growth factor receptors that
activate phosphatidylinositol 3-kinase.
Methods: We analysed the expression of the isoforms Akt1
and Akt2 as well as phosphorylated Akt (pAkt) by immuno-
histochemistry in frozen tumour samples from 280 post-
menopausal patients who participated in a randomised trial
comparing cyclophosphamide–methotrexate–5-fluorouracil chemo-
therapy and postoperative radiotherapy. The patients were
simultaneously randomised to tamoxifen or to no endocrine
treatment.
Results: Marked staining was found in 24% of the tumours for
Akt1, but in only 4% for Akt2. A low frequency of Akt2-positive
cells (1–10%) was observed in another 26% of the tumours.
pAkt was significantly associated with both Akt1 and Akt2
expression. Overexpression of erbB2 correlated significantly
with pAkt (P=0.0028). The benefit from tamoxifen was
analysed in oestrogen receptor (ER)-positive patients. Patients
with a negative status of Akt (no overexpression of Akt1, Akt2
or pAkt) showed significant benefit from tamoxifen. The relative
rate of distant recurrence, with versus without tamoxifen, was
0.44 (95% confidence interval [CI], 0.25–0.79) for ER+/Akt1–
patients, while it was 0.72 (95% CI, 0.34–1.53) for ER+/Akt1+
patients. The difference in rate ratio did not reach statistical
significance. The rate of locoregional recurrence was
significantly decreased with radiotherapy versus chemotherapy
for Akt-negative patients (rate ratio, 0.23; 95% CI, 0.08–0.67;
P=0.0074), while no benefit was evident for the Akt-positive
subgroup (rate ratio, 0.77; 95% CI, 0.31–1.9; P=0.58). The
interaction between Akt and the efficacy of radiotherapy was
significant in multivariate analysis (P=0.042).
Conclusion: Activation of the Akt pathway is correlated with
erbB2 overexpression in breast cancer. The results suggest
that Akt may predict the local control benefit from radio-
therapy.
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receptors and members of the epidermal growth factor-
receptor family (reviewed in [2,3]). The receptor most
analysed in breast cancer is the erbB2 receptor, also
known as HER-2/neu, and its overexpression has shown
prognostic significance in a number of studies (reviewed
in [4]). The growth factor receptors utilise several sig-
nalling pathways, such as the ras/mitogen-activated
protein kinase pathway that is important for mitogenic
stimulation. Other receptor signals are transmitted by the
phosphatidylinositol 3-kinase (PI3-K)/Akt pathway. The
activation of this pathway has proven important for cell
survival, and inhibitors have been shown to facilitate apop-
tosis and to sensitise cells to cytotoxic drugs in experi-
mental studies [5–8]. Proteins that participate in this
signalling might therefore be good candidates for predict-
ing the result of therapy.
The serine/threonine kinase Akt, or protein kinase B, is a
downstream effector of PI3-K. Akt is important in mediat-
ing several metabolic actions of insulin, while another
major activity is to mediate cell survival [5,9–11]. Among
several mechanisms, Akt inhibits apoptosis by phosphory-
lating the Bcl-2 family member Bad and by preventing the
release of cytochrome c from mitochondria [12–14]. Over-
expression of Akt therefore may contribute to tumour
development and progression. This is further supported by
the tumour suppressor PTEN, which is frequently mutated
or deleted in a large number of human cancers, inactivat-
ing the PI3-K/Akt pathway [15–18].
Akt1, Akt2 and Akt3 are three isoforms with high
sequence homology encoded by three separate genes
[19–21]. Akt1 is the predominant isoform in most tissues,
whereas the highest expression of Akt2 has been
observed in the insulin-responsive tissues [22]. Amplifica-
tion of the Akt2 gene has been found in some cases of
ovarian cancer, breast cancer and pancreatic cancer
[23–25].
In the present study we have analysed Akt1 and Akt2
protein expression as well as Akt phosphorylated at serine
473 (pAkt) in tumour samples from 280 postmenopausal
breast cancer patients. These patients participated in a ran-
domised trial comparing adjuvant cyclophosphamide–
methotrexate–5-fluorouracil (CMF) chemotherapy and post-
operative radiotherapy. The patients were simultaneously
randomised to tamoxifen or to no endocrine treatment.
Materials and methods
Patients
In 1976 the Stockholm Breast Cancer Group initiated a
trial to compare postoperative radiotherapy with adjuvant
chemotherapy [26]. The trial included premenopausal and
postmenopausal patients with a unilateral, operable breast
cancer. Using a 2×2 factorial study design, the post-
menopausal patients were also randomised between
either tamoxifen treatment or no endocrine treatment.
There was thus a total of four treatment groups: adjuvant
chemotherapy, adjuvant chemotherapy plus tamoxifen,
radiotherapy, and radiotherapy plus tamoxifen. Tamoxifen
was given postoperatively at a dose of 40mg daily for 2 or
5 years. Surgery consisted of modified radical mastec-
tomy. The patients were required to have either histologi-
cally verified lymph node metastases or a tumour diameter,
measured on the surgical specimen, exceeding 30mm.
Patient accrual started in November 1976 and ended in
April 1990. The current study included a subset consist-
ing of 280 postmenopausal patients for whom frozen
tumour tissue was still available after hormone receptor
assays had been performed in routine practice (Table 1).
Radiotherapy was given with a high-voltage technique.
The dose was 46Gy with 2Gy per fraction 5 days a week
for a total treatment time of about 4.5 weeks. The target
volume included the chest wall, the axilla, the supraclavic-
ular fossa and the internal mammary nodes. For most of
the patients randomised to chemotherapy, the treatment
consisted of 12 courses of CMF according to the original
Milan protocol (100mg/m2 cyclophosphamide orally at
days 1–14, 40mg/m2 methotrexate intravenously on days
1 and 8, and 600mg/m2 5-fluorouracil intravenously on
days 1 and 8). During the first 18 months of the trial,
however, cyclophosphamide was replaced by 10–15mg
chlorambucil orally on days 1–8, and up to 18 months was
allowed for the 12 courses to avoid dose reductions. The
patients were followed for a median period of 11 years. A
distant recurrence was registered in 126 patients and a
locoregional recurrence was registered in 48 cases.
Immunohistochemistry
The expression of Akt1, Akt2 and pAkt was analysed with
immunohistochemistry. Goat polyclonal antibodies against
Akt1 and Akt2 (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA), and a sheep polyclonal antibody against
the phosporylated serine residue in position 473 of human
Akt-1 (Upstate Biotechnology, Lake Placid, NY, USA)
were used for immunostaining. The latter antibody might
cross-react with other activated isoforms of Akt. In nega-
tive controls the primary antibodies were replaced by IgG
immunoglobulins (Sigma Chemical Co., St Louis, MO,
USA). Frozen sections of 5µm were cut from the tumours
and the slides were kept frozen until they were used for
Table 1
The number of patients allocated to different adjuvant therapies
No tamoxifen Tamoxifen
Postoperative radiotherapy 60 60
Chemotherapy (CMF) 82 78
CMF, cyclophosphamide–methotrexate–5-fluorouracil.R39
immunohistochemistry. The sections were fixed in acetone
(4°C) for 10 min. Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide in methanol for
5 min, and thereafter the sections were incubated with
normal swine serum (10%) for 10 min in order to block
nonspecific immunostaining. The specimens were then
incubated with the primary antibodies (8µg/ml for Akt1
and Akt2, 1µg/ml for pAkt) at room temperature for
60 min, or overnight at 4°C (pAkt), followed by incubation
with a biotinylated swine multilink antibody and strepta-
vidin conjugated with horseradish peroxidase for 30 min
each. The slides were finally stained with 3.3-diaminoben-
zidine tetrahydrochloride, counterstained with haema-
toxylin, dehydrated in a series of ethanols and mounted.
Tumours strongly positive for the Akt kinases were used
for positive controls, which were included in each batch.
The tumours were scored independently by two investiga-
tors. Tumours with clearly stained cells were further
scored taking into account the frequency of immuno-
stained malignant cells (>10% or <10%). The staining
was not evaluated due to poor quality of the sections in
eight cases for Akt1, in 10 cases for Akt2 and in six cases
for pAkt.
ErbB2 protein expression
ErbB2 protein expression was quantified with an immuno-
cytochemical method using flow cytometry as has been
described elsewhere [27]. Cell suspensions were pre-
pared by mechanical disintegration of frozen tumour
tissue, filtered and were fixed in 1% paraformaldehyde for
3 min at room temperature. The cells were incubated
either with the c-neu antibody (Ab-2, clone 9G6; Onco-
gene Research Products, Cambridge, MA, USA) or with
IgG1 immunoglobulins (Sigma Chemical Co.) as a control
(both 0.5µg/ml). Thereafter, a secondary FITC-conjugated
antibody (Dako, Glostrup, Denmark) was added. Samples
were analysed with a FACSCalibur flow cytometer
(Becton Dickinson, San Diego, CA, USA) equipped with a
15mW argon laser for excitation of FITC. A measure of
erbB2 expression was calculated from the paired
samples. The cut-off threshold used for erbB2 overexpres-
sion was the same as that used in previous studies
[28,29].
Statistical methods
The rates of recurrence in relation to treatment and other
variables were estimated and tested using Cox’s propor-
tional hazards model [30]. A test for the potential interaction
between Akt and the benefit from treatment was performed
by a Cox model including the covariates Akt, treatment, and
the interaction term treatment×Akt. The product-limit
method was used for estimation of cumulative probabilities
of recurrence-free survival [31]. Relationships between
grouped variables were tested by means of chi-square tests
for contingency tables with ordered categories.
Results
The results of the immunostaining for Akt1, Akt2 and pAkt
are presented in Table 2. All three forms exhibited cytoplas-
mic staining, to some extent localised to the cell membrane
(Fig.1). The staining patterns for Akt1 and Akt2 were differ-
ent. In the immunopositive tumours, Akt1 was frequently
expressed in a high percentage of cells, whereas the stain-
ing of Akt2 was mostly sparse. Most normal cells were
negative for the Akt kinases. However, the basal cells of
ductal structures stained positive for Akt1.
Regarding positive immunostaining in more than 10% of
the cells, pAkt staining was significantly associated with
both Akt1 and Akt2 staining (Table 3), although the corre-
lation was stronger for Akt1 (P<0.001) than for Akt2
(P=0.020). There was also a significant correlation
between Akt1 and Akt2 staining (P<0.001). Akt1 was not
significantly associated with other tumour characteristics,
including lymph node status, tumour size, ER status and
erbB2. Akt2-positive tumours were more often ER-nega-
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Table 2
The immunohistochemical score for Akt1 (n=272), Akt2
(n=270) and phosphorylated Akt (pAkt) (n=274)
% immunostained cells
0% 1–10% >10%
Akt1 192 (70) 15 (6) 65 (24)
Akt2 189 (70) 71 (26) 10 (4)
pAkt 136 (50) 63 (23) 75 (27)
Data presented as n (%).
Figure 1
Immunostaining of (a, b) Akt1, (c) Akt2 and (d) phosphorylated Akt.tive than other tumours (P=0.030). Overexpression of
erbB2 was significantly associated with pAkt; 44% of the
erbB2-positive tumours showed pAkt staining in more
than 10% of the cells, as compared with 22% of the
tumours with a negative erbB2 status (P=0.0028).
Tumours that simultaneously expressed Akt1 and Akt2
were more often erbB2-positive than other tumours
(P=0.040).
The benefit from tamoxifen in relation to ER, Akt and
erbB2
The benefit from tamoxifen in terms of improved distant
recurrence-free survival was restricted to ER-positive
patients. The relative rate of distant recurrence comparing
patients who were treated with adjuvant tamoxifen or were
not was 0.56 (95% confidence interval [CI], 0.36–0.87)
for the ER-positive group, while it was 1.3 (95% CI,
0.72–2.5) for ER-negative patients. The difference in rela-
tive rate was statistically significant (P=0.024).
We next investigated a possible interaction between the
expression of Akt and the benefit from tamoxifen for ER-
positive patients. To increase the statistical power,
patients whose tumours showed strong staining (>10%)
for either Akt1, Akt2 or pAkt were grouped together and
were defined as Akt-positive. The benefit from tamoxifen
was largely confined to ER+/Akt– patients (Fig.2). In this
group, adjuvant tamoxifen decreased the risk of distant
recurrence by 56% (rate ratio [RR]=0.44; 95% CI,
0.25–0.79), while the risk reduction was not statistically
significant for Akt-negative patients (RR=0.72; 95% CI,
0.34–1.53). The interaction between Akt and tamoxifen
did not reach statistical significance in multivariate analysis
that also included other tumour characteristics (P=0.28;
Table 4). Likewise, the erbB2 status failed to predict the
benefit from tamoxifen; however, the ER+/erbB2+ sub-
group comprised only 39 patients (data not shown).
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Table 3
The interrelationship between Akt1, Akt2 and phosphorylated Akt (pAkt) immunostaining
Akt2 immunostaining pAkt immunostaining
0% 1–10% >10% 0% 1–10% >10%
Akt1
0 149 (78) 35 (18) 6 (3) 99 (52) 42 (25) 43 (26)
1–10% 9 (60) 6 (40) 0 (0) 10 (67) 3 (20) 2 (13)
>10% 31 (48) 30 (46) 4 (6) 26 (40) 9 (14) 30 (46)
Akt2
0 91 (48) 49 (26) 48 (26)
1–10% 40 (57) 10 (14) 20 (29)
>10% 3 (30) 1 (10) 6 (60)
Data presented as n (%).
Figure 2
Distant recurrence-free survival for oestrogen receptor (ER)-positive
patients treated with tamoxifen (TAM) or not (no TAM) in relation to Akt
status.
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The benefit from chemotherapy versus radiotherapy in
relation to Akt and erbB2
The distant recurrence-free survival was similar for
patients assigned to adjuvant CMF chemotherapy and to
postoperative radiotherapy (RR=1.01; 95% CI,
0.71–1.42). The same was true in subgroups of patients
divided by Akt or erbB2 status (data not shown).
Postoperative radiotherapy is known to have a significant
protective effect upon locoregional relapse. In the present
study the irradiated patients had a significantly reduced
risk of locoregional recurrence compared with those
receiving chemotherapy (RR=0.38; 95% CI, 0.20–0.75;
P=0.0027). As shown in Figure 3, the benefit from radio-
therapy was higher in Akt-negative patients (RR=0.23;
95% CI, 0.08–0.67) compared with Akt-positive patients
(RR=0.77; 95% CI, 0.31–1.9). The interaction between
Akt and treatment was statistically significant when
analysed together with other variables (P=0.042;
Table 5). Similarly, there was a difference in the efficacy of
radiotherapy versus CMF comparing erbB2-negative
patients and erbB2-positive patients (RR=0.25; 95% CI,
0.10–0.65 and RR=0.78; 95% CI, 0.29–2.1, respec-
tively). The interaction between erbB2 and treatment did
not reach statistical significance in a multivariate model,
where Akt was replaced by erbB2 (P=0.095).
Discussion
During the past few years the association between Akt
and cancer has become evident. One of the major func-
tions of Akt is to promote growth-factor-mediated cell sur-
vival and to block apoptosis. The importance of Akt is
demonstrated by the wide range of tissues in which the
antiapoptotic activity has been shown. We observed stain-
ing for Akt1 in epithelial cells along the basement mem-
brane. Activation of Akt suppresses anoikis, a process
Table 4
Multivariate analysis of distant recurrence in oestrogen
receptor-positive patients including the variables lymph node
status, tumour size, Akt, treatment, and the interaction term
Akt×tamoxifen
Number Rate Test  for
of patients ratio significance (P)
Number of positive nodesa
01 9 1 . 0
1–3 119 4.3 0.000078
>3 58 7.4
Tumour size (mm)a
≤20 89 1.0
21–30 62 1.5 0.0031
>30 45 2.7
Aktb
Akt– 107 1.0
Akt+ 78 0.53 0.038
Radiotherapy/chemotherapyb
Radiotherapy 86 1.0
CMF chemotherapy 110 0.91 0.65
Tamoxifenb
No tamoxifen 100 1.0
Tamoxifen 96 0.40 0.0010
Akt×tamoxifen
0 147 1.0
1 38 1.7 0.28
CMF, cyclophosphamide–methotrexate–5-fluorouracil.
a The variable was coded 0, 1, 2.
b The variable was coded 0, 1.
Figure 3
Locoregional recurrence-free probability for patients treated with
postoperative radiotherapy (RT) or cyclophosphamide–methotrexate–
5-fluorouracil (CMF) chemotherapy in relation to Akt status.
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P = 0.58when apoptosis is induced by disruption of the interaction
between epithelial cells and the extracellular matrix
[32,33]. Cancer cells have the capability to survive
although they are detached from their normal structures,
and activation of Akt may play a role in this process.
Some cell lines that overexpress erbB2 have shown high
levels of Akt1 [34], and we hypothesised that there might
be a correlation between erbB2 and Akt expression in
breast tumours. We found a significant correlation
between erbB2 and pAkt, whereas a correlation between
erbB2 and Akt expression was found only for tumours that
coexpressed Akt1 and Akt2. Bacus et al. [35] recently
reported on a correlation between erbB2 and Akt2. Possi-
bly, erbB2 overexpression is implicated in the activation of
both Akt1 and Akt2, in keeping with the fact that positive
staining for pAkt may reflect phosphorylation of either of
the isoforms. We previously found a correlation between
stromal expression of heregulin β1 and phosphorylated
Akt in the malignant cells, further supporting a role of
erbB2/erbB3 signalling for activation of Akt [36].
Amplification or increased activation of Akt2 is a relatively
common event in ovarian cancer, particularly in advanced
stages [7,24]. Gene amplification of Akt2 was found in
3% of the tumours in a breast cancer study [24], a figure
that corresponds well to the number of cases with the
highest score for Akt2 in the present study (Table 2). We
found staining for Akt2 more frequently in ER-negative
tumours. In contrast, Akt1 was expressed with similar fre-
quencies in ER-positive tumours and in ER-negative
tumours. Akt1 is expressed to various degrees in breast
cancer cell lines and has been shown to be important in
oestrogen-stimulated growth [34]. This was recently sug-
gested also to be true for Akt2 [37]. Akt3 has not been
extensively studied in human cancer, although a high
expression level was associated with ER-negative breast
cancer in one study [38]. Inhibition of the PI3-K/Akt
pathway counteracts the accumulation of cyclin D1 that
normally is required for the G1/S transition following
oestrogen stimulation [39].
The patients in the present study were randomised to adju-
vant tamoxifen or to no endocrine treatment. The benefit
from tamoxifen, in terms of an improved distant recurrence-
free survival, was confined to ER-positive patients. Further
analysis of ER-positive patients suggested that the benefit
might also be related to Akt status (Fig.2). However, this
result is not really conclusive because the interaction
between Akt and the effect of tamoxifen was not signifi-
cant. This may be because of low statistical power or, alter-
natively, because other factors are more important for the
prediction of tamoxifen therapy. However, it was recently
shown that both PI3-K and Akt are capable of phosphory-
lating the ER at the activation function-1 site [37,40], and
inhibition of Akt increased tamoxifen-induced apoptosis
[40]. Moreover, tamoxifen may induce transforming growth
factor  β1 expression, and transforming growth factor
β1-induced apoptosis is suppressed through the same
pathway [41]. Furthermore, in a study of premenopausal
patients, who all received endocrine treatment, we found
pAkt to predict a worse outcome [36].
We defined Akt-positive patients as those showing strong
staining with at least one of the different Akt antibodies. In
part this was made to gain statistical power, but it may
also be motivated from a biological point of view. The
downstream targets relevant to cancer development are
probably shared by the different Akt kinases [42]. Further-
more, some cells with activated Akt may not be recog-
Breast Cancer Research    Vol 5 No 2 Stål et al.
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Table 5
Multivariate analysis of locoregional recurrence including the
variables lymph node status, tumour size, oestrogen receptor
(ER) status, Akt, treatment, and the interaction term Akt ×
radiotherapy
Number Rate Test  for
of patients ratio significance (P)
Number of positive nodesa
03 2 1 . 0
1–3 149 16.8 0.000008
>3 84 31.1
Tumour size (mm)a
≤20 111 1.0
21–30 78 2.6 0.00031
>30 76 5.7
ER statusb
ER– 78 1.0
ER+ 187 0.56 0.060
Aktb
Akt– 155 1.0
Akt+ 110 0.71 0.33
Tamoxifenb
No tamoxifen 132 1.0
Tamoxifen 133 0.65 0.17
Radiotherapy/chemotherapyb
CMF chemotherapy 152 1.0
Radiotherapy 113 0.22 0.0065
Akt × radiotherapy
0 221 1.0
1 44 4.3 0.042
CMF, cyclophosphamide–methotrexate–5-fluorouracil.
a The variable was coded 0, 1, 2.
b The variable was coded 0, 1.nised by the antibody against the phosporylated serine
residue at position 473, as this is not the only phosporyla-
tion site of Akt.
In a previous study of 5 years versus 2 years of tamoxifen
treatment, we found a decreased benefit from prolonged
treatment in relation to erbB2 overexpression [29]. The
erbB2 status failed to be predictive in the present study,
which is similar to the results presented by Berry et al.
[43]. In both these studies tamoxifen was given in addition
to chemotherapy, which makes the interaction between
erbB2 and treatment more complicated. However, too
small a number of ER+/erbB2+ patients may be another
reason for the lack of statistical significance.
Some experimental studies have found an interaction
between the activity of Akt and the response to cytotoxic
agents. Ovarian cancer cells overexpressing Akt were
more resistant to paclitaxel than cancer cells expressing
low Akt levels [6]. Inhibitors of PI3-K were found to
increase apoptosis induced by UV treatment and hypoxia
in breast cancer cells overexpressing erbB2 [35].
Decreased response to different cytotoxic drugs and
gamma irradiation was reported in human glioblastoma
cells after treatment with the multifunctional growth factor
scatter factor/hepatocyte growth factor, which activates
the PI3-K/Akt pathway [44]. Activation of Akt by scatter
factor/hepatocyte growth factor not only inhibited apopto-
sis after DNA damage, but also activated DNA repair [45].
Altiok et al. [46] showed that the multifunctional BRCA1
protein, which is implicated in DNA repair, is phosphory-
lated by Akt after treatment with heregulin.
In line with these findings, Akt-positive patients showed
decreased benefit from radiotherapy as concerns the
locoregional control in the present study. Likewise, the
efficacy of radiotherapy tended to be decreased for
erbB2-positive patients. Node-positive patients treated
with radiotherapy showed an increased risk of loco-
regional recurrence in relation to erbB2 overexpression in
a previous study [28]. In the present study, none of the
factors investigated showed any interaction with the effect
of CMF chemotherapy versus radiotherapy for distant
metastasis. Probably, the overall benefit from CMF was
moderate in this series of postmenopausal women, as the
rate of distant recurrence was similar in the chemotherapy
and radiotherapy group.
The results of the present study do not indicate Akt as a
pure prognostic factor, but rather it may be of importance
for predicting the treatment effect. It is evident from the
survival curves as well as from the multivariate analyses
(Tables 4 and 5) that a positive Akt status was not associ-
ated with a worse outcome among patients not receiving
tamoxifen or, in terms of locoregional recurrence, among
patients not receiving radiotherapy.
Conclusion
This is the first study of Akt in a randomised material of
breast cancer. We conclude that activation of Akt is corre-
lated with erbB2 overexpression and with decreased local
control benefit from radiotherapy. Further studies are
needed to confirm this and also to prove whether the
PI3-K/Akt pathway is important for the result of endocrine
treatment. If so, this pathway should be an interesting
target for new drugs.
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